ABOUT THIS CONFERENCE
Kinases are now well established as a validated drug target class in cancer. However new light is being shed on their role in helping cancers resistant to conventional chemotherapy, representing topics that will be covered within this conference. Attendees will also learn about progress on promising preclinical and early clinical phase kinase inhibitor drug candidates in therapeutic areas beyond cancer, such as inflammation. Another focus of the Novel Strategies for Kinase Inhibitors conference will be on assay development and interpretation for new types of kinase inhibitors such as allosteric modulators and covalent inhibitors.
SUGGESTED EVENT PACKAGE:
September 23: New Class of Kinase Inhibitors: Covalent Modifiers Short Course
September 23: Advancing Tools and Technologies for Fragment-Based Design Short Course
September 24 - 25: Novel Strategies for Kinase Inhibitors Conference
September 25 - 26: Cardio-Metabolic Drug Targets Conference
Scientific Advisory Board:
Jordan S. Fridman, Ph.D., Senior Director, Pharmacology, Incyte Corp.
William J. Pitts, Ph.D., Group Leader, Medicinal Chemistry, Bristol-Myers Squibb Co.
John Robinson, Ph.D., Senior Scientist, Medicinal Chemistry, Array BioPharma, Inc.
Deregulated Cdk5-Targeted Inhibitor for Neuro-inflammation
Harish C. Pant, Ph.D., Chief, Laboratory of Cytoskeleton Protein Regulation, National Institute of Neurological Disease and Stroke, NIH
BTK Inhibitors in Inflammation and Autoimmunity
John Douhan III, Ph.D., Senior Principal Scientist, Immunoscience, Pfizer
Second Generation Janus Kinase Inhibitors
Jordan S. Fridman, Ph.D., Senior Director, Pharmacology, Incyte Corp.
ARRY-382, a Selective cFMS inhibitor for the Treatment of Osteolytic Bone Diseases
Dale Wright, Ph.D., Research Investigator, Senior Project Leader, Pharmacology, Array BioPharma Inc.
JNK Inhibitor Discovery at Celgene - Tanzisertib and Beyond
Yoshitaka Satoh, Ph.D., Senior. Principal Scientist, Medicinal Chemistry, Celgene
Highly Selective Allosteric FMS Kinase inhibitors
Bryan Smith, Ph.D., Senior Scientist II, Biology, Deciphera Pharmaceuticals LLC
Exploiting a Serendipitous Binding Opportunity in the Development of Highly Selective Rho Kinase Inhibitors
Erick Young, Ph.D., Distinguished Research Fellow, Medicinal Chemistry and Research Administration, Boehringer Ingelheim Pharma
The Role of Growth Factors in Resistance to Anti-Cancer Kinase Inhibitors
Jeffrey Settleman, Ph.D., Senior Director, Discovery Oncology, Genentech
mTOR inhibitor Torin-1 for Targeting of Resistant Human Colon Cancer Stem Cells
Maria Giovanna Francipane, Ph.D., Post-Doctoral Research Scholar, Pathology, University of Pittsburgh
Development of c-MET kinase Inhibitors for Drug Resistant Cancers
Xiangdong Liu, Ph.D., Drug Discovery, Incyte Corporation